NCT06973291

A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

A Phase 3, Randomized, Multicenter, Double-Blind Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib (TAK-279) Compared to Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 606 (actual)
• Sponsor: Takeda · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque psoriasis. Participants will take one tablet daily of either zasocitinib or a matching placebo, along with one capsule daily of either over-encapsulated deucravacitinib or a matching placebo, for a duration of 16 weeks. Participants will be in the study for up to 25 weeks, which includes screening period of up to 35 days, a 16-week treatment period, and a 4-week safety follow-up period.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Zasocitinib	Zasocitinib tablets.
DRUG	Deucravacitinib	Deucravacitinib capsules.
DRUG	Placebo to match zasocitinib	Zasocitinib matching placebo tablets.
DRUG	Placebo to match deucravacitinib	Deucravacitinib matching placebo capsules.

Timeline

• Start date: 2025-07-09
• Primary completion: 2026-06-05
• Completion: 2026-07-03
• First posted: 2025-05-15
• Last updated: 2025-12-17

Locations

113 sites across 8 countries: United States, Bulgaria, Canada, Czechia, France, Japan, Latvia, Poland

Regulatory

• FDA-regulated drug study